Whole Exome Sequencing (WES): Questions and Answers for Providers
|
|
- Roger Gregory
- 5 years ago
- Views:
Transcription
1 Whole Exome Sequencing (WES): Questions and Answers for Providers 1. What is Whole Exome Sequencing? What is the difference between Whole Exome Sequencing (WES) and Whole Exome Sequencing Plus Pharmacogenomics (WESPP)? What paperwork and clinical information is requested for WES? Is it required? What sample types are accepted? Are parental samples required for WES? What if both of the patient s biological parents are not available for testing? If the patient s parents are not available for testing, can I send samples from other family members to complete the required trio? If other family members share the same phenotype as the proband, can they also be tested? Which variants will be reported and how will they be categorized on the report? What is the policy for reporting secondary findings? Are parental results reported? Are mitochondrial variants assessed? Is carrier status reported for conditions recommended by ACMG or ACOG for reproductive carrier screening? How are results reported? What is the turnaround time? What types of variants are not detected by this test? Are there genes that are not evaluated by WES? What is the depth of coverage for WES? What is the sensitivity of WES for detecting single nucleotide variants? What size insertions/deletions can the lab reliably detect? How are variants classified? How are variants filtered? What method is being used for WES testing? Do you perform Sanger verification of detected variants? Can WES reveal that 1 of the patient s parents is not related to the patient (ie,nonpaternity, nonmaternity, or adoption)? Can you perform reanalysis of a patient s exome? Can I have a copy of the patient s raw data? Can I order targeted testing for the relative of a patient whose variant was identified by WES? What is the cost of the test? What are the CPT codes for WES?... 4 References... 5 Table 1. Genes analyzed in WES for secondary findings Mayo Foundation for Medical Education and Research Page 1 of 6
2 1. What is Whole Exome Sequencing? Whole Exome Sequencing is a next-generation sequencing test that evaluates patients with suspected genetic disorders for germline mutations within the coding regions (exons) of approximately 23,000 genes. 2. What is the difference between Whole Exome Sequencing (WES) and Whole Exome Sequencing Plus Pharmacogenomics (WESPP)? Pharmacogenomic variants are not evaluated when Whole Exome Sequencing (WES) is ordered. WESPP includes evaluation of pharmacogenomic variants in 11 genes: CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4, CYP3A5, HLA-A, HLA-B, SLCO1B1, UGT1A1, and VKORC1. For additional information about WESPP, please refer to the LTC or the Whole Exome Sequencing Plus Pharmacogenomics (WESPP): Questions and Answers for Providers document 3. What paperwork and clinical information is requested for WES? Is it required?.thorough clinical information is required for the most accurate interpretation of variants identified by whole exome sequencing. In order to ensure appropriate interpretation of your patient s test results, the Patient Information and Informed Consent forms are required. This paperwork is available as a fillable PDF that consists of: Ordering Checklist (page 1) Patient Information (pages 2-4) Informed Consent Form (pages 5-7) Please also submit the following: Clinic notes from specialists relevant to the patient s clinical features A 3-generation pedigree.please send all paperwork with the samples. Although not required, a faxed copy of the paperwork can also be sent directly to the Molecular Genetics Laboratory, Attn: WES Genetic Counselors at What sample types are accepted? WES is currently validated on peripheral whole blood samples only..if insurance preauthorization is being requested prior to testing, CRYO / Cryopreservation for Molecular Genetic Studies can also be ordered. Please contact the Molecular Genetics laboratory to request WES testing on a cryopreserved sample. 5. Are parental samples required for WES? Yes, samples from the patient and both biological parents (trio) are required. Whole exome sequencing is performed on all members of the trio in order to determine the inheritance pattern of all variants. Interpretation of variants is more accurate when the laboratory is able to compare the results between the parents and their child. 6. What if both of the patient s biological parents are not available for testing? Because a trio including the patient and both biological parents is required for WES, testing cannot be completed without both parental samples. 7. If the patient s parents are not available for testing, can I send samples from other family members to complete the required trio? No, the trio must include the patient and both biological parents in order to proceed with WES. 8. If other family members share the same phenotype as the proband, can they also be tested? Samples from additional affected family members outside of the trio may be accepted on a case-by-case basis. Although whole exome sequencing will not be performed on samples from additional affected family members outside of the trio, these samples may be tested for variants of interest identified in the proband to assess segregation. For more information, call Mayo Clinic Laboratories at and ask to speak with a WES genetic counselor. 9. Which variants will be reported and how will they be categorized on the report? Variants will be reported in the following categories: Likely Causative Variants Possibly Relevant Variants Variants in Genes of Uncertain Significance (GUS) Note: Variants in GUS will only be reported if there is a high degree of suspicion that they may be causative of a patient s reported clinical features. Secondary Findings (unless the patient opts-out of receiving these results on the informed consent form) Note: Secondary findings will only be reported if they are in 1 or more of the 59 genes recommended by the American College of Medical Genetics and Genomics (ACMG). Refer to question 10 and Table 1 for more details. Page 2 of 6
3 10. What is the policy for reporting secondary findings? Secondary findings will be assessed and reported in accordance with the American College of Medical Genetics and Genomics (ACMG) Recommendations for Reporting of Secondary Findings in Clinical Exome and Genome Sequencing, 2016 Update(1), unless the patient opts-out of receiving these results on the informed consent form. ACMG s recommendations include the analysis of variants in 59 genes associated with cardiac conditions, cancer predisposition, and other genetic syndromes. Please see Table 1 at the end of this document for a list of the genes and associated syndromes included in ACMG s recommendations. Only variants identified in these 59 genes will be reported as secondary findings. In accordance with ACMG recommendations, only variants that are known or expected to be pathogenic will be reported and novel missense variants will not be further evaluated as secondary findings. Variants of uncertain significance in these genes will not be reported (unless they are in a gene associated with the patient s reported clinical features). 11. Are parental results reported? The parent from whom a reported variant was inherited will be stated on the proband s report. Parents will not receive a separate interpretative report. 12. Are mitochondrial variants assessed? Variants in nuclear encoded mitochondrial genes will be assessed. However, mitochondrial DNA is not sequenced as part of WES and therefore variants in these genes are not reported. If analysis of mitochondrial DNA is desired, consider ordering a mitochondrial DNA sequencing test. 13. Is carrier status reported for conditions recommended by ACMG or ACOG for reproductive carrier screening? No, carrier status for conditions recommended by ACMG or ACOG for reproductive carrier screening is not specifically evaluated or reported unless the patient is found to have a variant in a gene for a condition that overlaps with the patient s reported clinical features. 14. How are results reported? WES results will be reported directly to the client laboratory and will be incorporated into the patient s medical record in accordance with individual institution processes. 15. What is the turnaround time? The turnaround time for WES is approximately 12 weeks. 16. What types of variants are not detected by this test? Due to the limitations of next-generation sequencing, the following variant types may not be detectable by this test: some insertions and deletions, structural chromosome rearrangements, polyploidy, intronic variants outside of the consensus splice site, variants in repetitive regions, variants occurring in regions with pseudogenes, mitochondrial variants, low-level mosaic variants, and other unknown abnormalities. 17. Are there genes that are not evaluated by WES? While WES targets the entire exome (coding areas of the genome), some genes may not be adequately evaluated due to poor coverage of a region in which a specific gene is located. At this time, greater than 95% of the exome can be sequenced well enough to be interpreted. Variants in genes lacking evidence of clinical significance and variants in genes unrelated to the patient s reported clinical features will not be evaluated (unless present in genes evaluated for medically actionable secondary findings in accordance with ACMG recommendations). Pharmacogenomic variants are not evaluated by WES. If pharmacogenomic results are desired, consider ordering WESPP / Whole Exome Sequencing Plus Pharmacogenomics. 18. What is the depth of coverage for WES? For each patient, 98.3% of the exome is covered at >10X, and 97% of the exome is covered at >20X. 19. What is the sensitivity of WES for detecting single nucleotide variants? With the depth of coverage metrics described above, this assay detects >99% of single nucleotide variants in the exome. 20. What size insertions/deletions can the lab reliably detect? With the depth of coverage metrics described above, this assay detects 95% of small insertions and deletions up to 30 bases in the exome. Genomic copy number variants are not assessed or reliably detected. CMACB / Chromosomal Microarray, Congenital, Blood should be ordered for formal evaluation of clinically relevant copy number variants. Page 3 of 6
4 21. How are variants classified? Variants are evaluated and classified as either benign, likely benign, variant of uncertain significance (VUS), likely pathogenic, or pathogenic in accordance with ACMG recommendations.(2) Variants classified as benign or likely benign are not reported. Variant classification may change over time if additional information becomes available. At this time, it is not standard practice for the laboratory to systematically review likely pathogenic variants and variants of uncertain significance that are detected and reported. Health care providers are encouraged to contact the laboratory to learn how the classification of a particular variant may have changed over time. 22. How are variants filtered? Inheritance pattern filtering is performed based upon the affected status of the proband s parents. Variants fitting any biologically plausible mechanism are evaluated further. Variants with a minor allele frequency greater than or equal to 1% are not typically evaluated. Unless previously reported as pathogenic or disease-causing in ClinVar or HGMD, the following variants may not be evaluated: low impact variants (synonymous, deep intronic, 5 /3 UTR, etc), variants in genes lacking evidence of clinical significance, and variants in genes unrelated to the patient s reported clinical features (unless present in genes evaluated for medically actionable secondary findings in accordance with ACMG recommendations). 23. What method is being used for WES testing? Whole exome sequencing is performed on genomic DNA extracted from all samples submitted. The exome is captured utilizing a custom reagent developed by Mayo Clinic and Agilent Technologies. Sequencing is performed on an Illumina HiSeq 2500 Next-generation sequencing instrument, using HapMap Sample NA12878 as an internal control. Paired-end 101 base-pair reads are aligned to a modified human reference genome (GRCh37/hg19) using Novoalign (Novocraft Technologies, Malaysia). Sequencing quality is evaluated using FastQC.(3) All germline variants are jointly called through GATK Haplotype Caller and GenotypeGVCF.(4) Each variant is annotated using the BioR Toolkit(5), and subsequently evaluated for clinical relevance by a team of scientists, genetic counselors, and laboratory directors. 24. Do you perform Sanger verification of detected variants? Variants of interest in the patient are confirmed by automated fluorescence dideoxy sequencing (aka Sanger sequencing), if technically necessary. 25. Can WES reveal that 1 of the patient s parents is not related to the patient (ie, nonpaternity, nonmaternity, or adoption)? WES requires samples from the patient and both biological parents in order to be able to compare variants found in the patient to those found in the parents. Thus, with this sequencing data it is possible to discover that a parent is unrelated to the patient (misattributed maternity or paternity). In this situation, no results will be generated. The ordering provider will be contacted by the laboratory to discuss available options. 26. Can you perform reanalysis of a patient s exome? A health care provider can request reanalysis of the patient s reported variants. Contact the laboratory and ask to speak with a WES genetic counselor for more information. 27. Can I have a copy of the patient s raw data? A health care provider can request the patient s raw data. A fee will be charged for the cost of the storage device. Contact the laboratory and ask to speak with a WES genetic counselor for more information. 28. Can I order targeted testing for the relative of a patient whose variant was identified by WES? Yes, FMTT / Familial Mutation Targeted Testing can be ordered for variants identified by WES. Documentation of the specific variants is required and must be provided with the sample in order to perform this test. Contact the laboratory and ask to speak with a WES genetic counselor for more information. 29. What is the cost of the test? Contact Mayo Clinic Laboratories ( ) for current pricing information. 30. What are the CPT codes for WES? The following CPT codes will be applied to the proband only: and x 2. Page 4 of 6
5 References 1. Kalia SS, Adelman K, Bale SJ, et al. Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics. Genet Med. 2016; Epub ahead of print 2. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5): McKenna A, Hanna M, Banks E, et al: The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 2010;20(9): Kocher JP, Quest DJ, Duffy P, et al: The Biological Reference Repository (BioR): a rapid and flexible system for genomics annotation. Bioinformatics 2014;30(13): Table 1. Genes analyzed in WES for secondary findings In accordance with ACMG recommendations for reporting of secondary findings in clinical exome and genome sequencing.(1) Gene Conditions Inheritance Pattern Variants Reported ACTA2 Marfan syndrome, Loeys Dietz syndromes, and familial thoracic aortic AD ACTC1 Hypertrophic or dilated cardiomyopathy AD KP APC Familial Adenomatous Polyposis AD APOB Familial Hypercholesterolemia SD KP ATP7B Wilson disease AR* BMPR1A Juvenile polyposis syndrome AD BRCA1 Hereditary Breast and Ovarian Cancer AD BRCA2 Hereditary Breast and Ovarian Cancer AD CACNA1S Malignant Hyperthermia Susceptibility AD KP COL3A1 Ehlers-Danlos Syndrome, Vascular Type AD DSC2 Arrhythmogenic Right-Ventricular Cardiomyopathy AD DSG2 Arrhythmogenic Right-Ventricular Cardiomyopathy AD DSP Arrhythmogenic Right-Ventricular Cardiomyopathy AD FBN1 Marfan syndrome, Loeys Dietz syndromes, and familial thoracic aortic AD GLA Hypertrophic or dilated cardiomyopathy XL KCNH2 Romano-Ward Long QT syndrome types 1, 2, and 3, Brugada Syndrome AD KCNQ1 Romano-Ward Long QT syndrome types 1, 2, and 3, Brugada Syndrome AD LDLR Familial Hypercholesterolemia SD LMNA Hypertrophic or dilated cardiomyopathy AD MEN1 Multiple Endocrine Neoplasia type 1 AD MLH1 Lynch syndrome AD MSH2 Lynch syndrome AD MSH6 Lynch syndrome AD MUTYH MYH-associated polyposis AR* MYBPC3 Hypertrophic or dilated cardiomyopathy AD MYH11 Marfan syndrome, Loeys Dietz syndromes, and familial thoracic aortic AD MYH7 Hypertrophic or dilated cardiomyopathy AD KP MYL2 Hypertrophic or dilated cardiomyopathy AD KP MYL3 Hypertrophic or dilated cardiomyopathy AD KP NF2 Neurofibromatosis type 2 AD OTC Ornithine transcarbamylase deficiency XL PCSK9 Familial Hypercholesterolemia AD KP PKP2 Arrhythmogenic Right-Ventricular Cardiomyopathy AD PMS2 Lynch syndrome AD PRKAG2 Hypertrophic or dilated cardiomyopathy AD KP PTEN PTEN Hamartoma Tumor Syndrome AD RB1 Retinoblastoma AD Page 5 of 6 Continued on next page
6 Continued Gene Conditions Inheritance Pattern Variants Reported RET Multiple Endocrine Neoplasia type 2; Familial Medullary Thyroid Cancer AD KP RYR1 Malignant Hyperthermia Susceptibility AD KP RYR2 Catecholaminergic Polymorphic Ventricular Tachycardia AD KP SCN5A Romano-Ward Long QT syndrome types 1, 2, and 3, Brugada Syndrome AD SDHAF2 Hereditary Paraganglioma-Pheochromocytoma syndrome AD KP SDHB Hereditary Paraganglioma-Pheochromocytoma syndrome AD SDHC Hereditary Paraganglioma-Pheochromocytoma syndrome AD SDHD Hereditary Paraganglioma-Pheochromocytoma syndrome AD SMAD3 Marfan syndrome, Loeys Dietz syndromes, and familial thoracic aortic AD SMAD4 Juvenile polyposis syndrome AD STK11 Peutz-Jeghers AD TGFBR1 Marfan syndrome, Loeys Dietz syndromes, and familial thoracic aortic AD TGFBR2 Marfan syndrome, Loeys Dietz syndromes, and familial thoracic aortic AD TMEM43 Arrhythmogenic Right-Ventricular Cardiomyopathy AD KP TNNI3 Hypertrophic or dilated cardiomyopathy AD KP TNNT2 Hypertrophic or dilated cardiomyopathy AD TP53 Li-Fraumeni syndrome AD TPM1 Hypertrophic or dilated cardiomyopathy AD KP TSC1 Tuberous sclerosis complex AD TSC2 Tuberous sclerosis complex AD VHL Von Hippel-Lindau syndrome AD WT1 WT1-Related Wilms Tumor AD *Homozygous and biallelic mutations will be reported only (carrier status will not be reported). AD = Autosomal dominant AR = Autosomal recessive EP = Expected pathogenic KP = Known pathogenic SD = Semidominant XL = X-linked Page 6 of 6
Informed Consent Columbia Whole Genome or Whole Exome Sequencing
Informed Consent Columbia Whole Genome or Whole Exome Sequencing Please read the following form carefully and discuss with your ordering physician before signing consent. This consent is intended for the
More informationNeurogenetics Genetic Testing and Ethical Issues
Neurogenetics Genetic Testing and Ethical Issues Grace Yoon, MD, FRCP(C) Divisions of Neurology and Clinical and Metabolic Genetics The Hospital for Sick Children Objectives 1) To recognize the ethical
More informationNo mutations were identified.
Hereditary Heart Health Test DOB: May 25, 1977 ID: 123456 Sex: Female Requisition #: 123456 ORDERING PHYSICIAN Dr. Jenny Jones Sample Medical Group 123 Main St. Sample, CA SPECIMEN Type: Saliva Barcode:
More informationCentoCancer STRIVE FOR THE MOST COMPLETE INFORMATION
CentoCancer STRIVE FOR THE MOST COMPLETE INFORMATION CentoCancer our most comprehensive oncogenetics panel for hereditary mutations Hereditary pathogenic variants confer an increased risk of developing
More informationMolecular Genetics Requisition Form 2. Clinical Whole Exome Sequencing Informed Consent 5. Clinical Whole Exome Sequencing Information & FAQ 12
NYGC CLINICAL WHOLE EXOME SEQUENCING Phone: 646-697-7106 Fax: 347-875-4100 Email: Clinical@nygenome.org TABLE OF CONTENTS Molecular Genetics Requisition Form 2 Clinical Whole Exome Sequencing Informed
More informationLMM / emerge III Network Reference Sequences October 2016 LMM / emerge III Network Consensus Actionable Gene List *ACMG56 gene
LMM / emerge III Network Consensus Actionable Gene List *ACMG56 gene ACTA2* Exon 02-09 NM_001613.2 DSG2* Exon 01-15 NM_001943.3 ACTC1* Exon 01-06 NM_005159.4 DSP* Exon 01-24 NM_004415.2 APC* Exon 01-15
More informationInformation for You and Your Family
Information for You and Your Family What is Prevention? Cancer prevention is action taken to lower the chance of getting cancer. In 2017, more than 1.6 million people will be diagnosed with cancer in the
More informationGenetic Risk Assessment for Cancer
Genetic Risk Assessment for Cancer Jennifer Siettmann, MS CGC Certified Genetic Counselor Banner MD Anderson Cancer Center Objectives Describe the role of genetic counseling and genetic testing in patient
More informationCode CPT Descriptor Test Purpose and Method Crosswalk Recommendation SEPT9 (Septin9) (e.g., colorectal cancer) methylation analysis
ASSOCIATION FOR MOLECULAR PATHOLOGY Education. Innovation & Improved Patient Care. Advocacy. 9650 Rockville Pike. Bethesda, Maryland 20814 Tel: 301-634-7939 Fax: 301-634-7995 amp@amp.org www.amp.org August
More informationNGS for Cancer Predisposition
NGS for Cancer Predisposition Colin Pritchard MD, PhD University of Washington Dept. of Lab Medicine AMP Companion Society Meeting USCAP Boston March 22, 2015 Disclosures I am an employee of the University
More informationClinical Cancer Genetics
Clinical Cancer Genetics Lisen Axell, MS, CGC University of Colorado Cancer Center Individuals with cancer Making surgical decisions (lump vs. mast) Making treatment decisions (XRT) Concerns for additional
More informationThe benefit of. knowing. Genetic testing for hereditary cancer. A patient support guide
The benefit of knowing Genetic testing for hereditary cancer A patient support guide Does cancer run in your family? Cancer is more common in some families. Sometimes cancer is caused by a change in a
More informationThe Next Generation of Hereditary Cancer Testing
The Next Generation of Hereditary Cancer Testing Why Genetic Testing? Cancers can appear to run in families. Often this is due to shared environmental or lifestyle patterns, such as tobacco use. However,
More informationMolecular Diagnostic Laboratory 18 Sequencing St, Gene Town, ZY Tel: Fax:
Molecular Diagnostic Laboratory 18 Sequencing St, Gene Town, ZY 01234 Tel: 555-920-3333 Fax: 555-920-3334 www.moldxlaboratory.com Patient Name: Jane Doe Specimen type: Blood, peripheral DOB: 04/05/1990
More informationGermline Testing for Hereditary Cancer with Multigene Panel
Germline Testing for Hereditary Cancer with Multigene Panel Po-Han Lin, MD Department of Medical Genetics National Taiwan University Hospital 2017-04-20 Disclosure No relevant financial relationships with
More informationGenetic Testing for Hereditary Cancer Susceptibility Syndromes
Medical Coverage Policy Genetic Testing for Hereditary Cancer Susceptibility Syndromes Table of Contents Effective Date... 1/15/2018 Next Review Date... 7/15/2018 Coverage Policy Number... 0518 Related
More informationMedical Policy Update
Medical Policy Update Summer 2017 Highlights of recent medical policy revisions as well as any new medical policies approved by Prevea360 Health Plan s Medical Policy Committee are shown below. The Medical
More informationWHAT IS A GENE? CHROMOSOME DNA PROTEIN. A gene is made up of DNA. It carries instructions to make proteins.
WHAT IS A GENE? CHROMOSOME E GEN DNA A gene is made up of DNA. It carries instructions to make proteins. The proteins have specific jobs that help your body work normally. PROTEIN 1 WHAT HAPPENS WHEN THERE
More informationChapter 2 Cancer and Genetic Counseling
Chapter 2 Cancer and Genetic Counseling Brandie Heald and James M. Church Introduction All cancer is genetic. Cancer is a disease caused by an accumulation of genetic damage that interferes with the regulation
More informationGenetic Risk Assessment for Cancer
Genetic Risk Assessment for Cancer Jennifer Siettmann, MS CGC Certified Genetic Counselor/Cancer Risk Counselor Banner Good Samaritan Cancer Screening & Prevention Program Objectives Describe the role
More informationCANCER GENETICS PROVIDER SURVEY
Dear Participant, Previously you agreed to participate in an evaluation of an education program we developed for primary care providers on the topic of cancer genetics. This is an IRB-approved, CDCfunded
More informationpatient guide CancerNext-Expanded genetic testing for hereditary cancer Because knowing your risk can mean early detection and prevention
patient guide CancerNext-Expanded genetic testing for hereditary cancer Because knowing your risk can mean early detection and prevention Know the Basics Cancer occurs in about 1 in 3 adults in their lifetime
More informationSYSTEMATIC ASSESSMENT OF CLINICAL ACTIONABILITY ASSOCIATED WITH GENOMIC VARIATION
1 SYSTEMATIC ASSESSMENT OF CLINICAL ACTIONABILITY ASSOCIATED WITH GENOMIC VARIATION Elizabeth M. Webber, MS Center for Health Research Kaiser Permanente Northwest February 23, 2017 Acknowledgements ClinGen
More informationWHAT IS A GENE? CHROMOSOME DNA PROTEIN. A gene is made up of DNA. It carries instructions to make proteins.
WHAT IS A GENE? CHROMOSOME GENE DNA A gene is made up of DNA. It carries instructions to make proteins. The proteins have specific jobs that help your body work normally. PROTEIN 1 WHAT HAPPENS WHEN THERE
More informationGenetic Testing for Familial Gastrointestinal Cancer Syndromes. C. Richard Boland, MD La Jolla, CA January 21, 2017
Genetic Testing for Familial Gastrointestinal Cancer Syndromes C. Richard Boland, MD La Jolla, CA January 21, 2017 Disclosure Information C. Richard Boland, MD I have no financial relationships to disclose.
More informationComprehensive Test Menu August 2018
Comprehensive Test Menu August 2018 Cancer brain tumors Brain tumors, hereditary BrainTumorNext: 27 genes 14-21 days 8847 Neurofibromatosis type 2 (NF2) NF2 14-21 days 9024 Schwannomatosis SMARCB1 14-21
More informationAssociation of Clinical Features With Incidental Findings From Exome Sequencing in 3,223 African Americans
Association of Clinical Features With Incidental Findings From Exome Sequencing in 3,223 African Americans The Harvard community has made this article openly available. Please share how this access benefits
More informationCOLON CANCER & GENETICS VERMONT COLORECTAL CANCER SUMMIT NOVEMBER 15, 2014
COLON CANCER & GENETICS VERMONT COLORECTAL CANCER SUMMIT NOVEMBER 15, 2014 WENDY MCKINNON, MS, CGC CERTIFIED GENETIC COUNSELOR FAMILIAL CANCER PROGRAM UNIVERSIT Y OF VERMONT MEDICAL CENTER 1 CHARACTERISTICS
More informationExpert Interview: Inherited Susceptibility to Cancer with Dr. Nicoleta Voian
Expert Interview: Inherited Susceptibility to Cancer with Dr. Nicoleta Voian ANNOUNCER OPEN: Welcome to CME on ReachMD. This segment, entitled Inherited Susceptibility to Cancer: What Do Primary Care Providers
More informationHereditary Cardiovascular Conditions. genetic testing for undiagnosed diseases
Hereditary Cardiovascular Conditions genetic testing for undiagnosed diseases What is Hypertrophic Cardiomyopathy (HCM)? normal heart heart with hcm Extra or thick heart muscle Typically in the left ventricle
More informationComprehensive Test Menu December 2018
Comprehensive Test Menu December 2018 Cancer brain tumors Brain tumors, hereditary BrainTumorNext: 27 genes 14-21 days 8847 Neurofibromatosis type 2 (NF2) NF2 14-21 days 9024 Schwannomatosis SMARCB1 14-21
More informationMEDICAL GENOMICS LABORATORY. Next-Gen Sequencing and Deletion/Duplication Analysis of NF1 Only (NF1-NG)
Next-Gen Sequencing and Deletion/Duplication Analysis of NF1 Only (NF1-NG) Ordering Information Acceptable specimen types: Fresh blood sample (3-6 ml EDTA; no time limitations associated with receipt)
More informationDNA Basics. We are all made up of cells. Cells contain DNA, or instructions to tell our bodies how to work.
DNA Basics We are all made up of cells. Cells contain DNA, or instructions to tell our bodies how to work. DNA is packaged into structures called chromosomes. Each chromosome contains many genes and each
More informationThe Genetics and Prevention of Sudden Cardiac Death
The Genetics and Prevention of Sudden Cardiac Death Sudden cardiac death (SCD), a serious public health problem Every day, between 1,600 and 2,000 people die worldwide from genetically caused SCD. 1 SCD
More informationAssessing Laboratory Performance for Next Generation Sequencing Based Detection of Germline Variants through Proficiency Testing
Assessing Laboratory Performance for Next Generation Sequencing Based Detection of Germline Variants through Proficiency Testing Karl V. Voelkerding, MD Professor of Pathology University of Utah Medical
More informationA guide to genetic testing for hereditary cancers
Cancer Testing Solutions A guide to genetic testing for hereditary cancers The benefit of knowing TM Hereditary cancer genetic testing can play a critical role in managing health Cancer touches millions
More informationHEREDITY & CANCER: Breast cancer as a model
HEREDITY & CANCER: Breast cancer as a model Pierre O. Chappuis, MD Divisions of Oncology and Medical Genetics University Hospitals of Geneva, Switzerland Genetics, Cancer and Heredity Cancers are genetic
More informationEthical Challenges of Genome-based Cancer Research: Return of individual research results
Ethical Challenges of Genome-based Cancer Research: Return of individual research results Gail P. Jarvik, M.D., Ph.D. Arno G. Motulsky Endowed Chair Medicine and Genome Sciences Head, Medical Genetics
More informationNo mutations were identified.
Hereditary High Cholesterol Test ORDERING PHYSICIAN PRIMARY CONTACT SPECIMEN Report date: Aug 1, 2017 Dr. Jenny Jones Sample Medical Group 123 Main St. Sample, CA Kelly Peters Sample Medical Group 123
More informationTGL clinical User Guide
TGL clinical User Guide The Institute of Cancer Research Brookes Lawley Building 15 Cotswold Road Sutton, Surrey SM2 5NG Page 1 of 7 TGL clinical This document describes the services provided by TGL clinical
More informationGermline Multigene Panel Testing in Oncology: Genetic Counseling Perspective
Germline Multigene Panel Testing in Oncology: Genetic Counseling Perspective Sarah L. Campian, MS CGC Certified Genetic Counselor Nancy & James Grosfeld Cancer Genetics Center Objectives Identify patients/families
More informationCorporate Medical Policy
Corporate Medical Policy Genetic Cancer Susceptibility Panels Using Next Generation File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_cancer_susceptibility_panels_using_next_generation_sequencing
More informationPROVIDER POLICIES & PROCEDURES
PROVIDER POLICIES & PROCEDURES GENETIC CANCER SUSCEPTIBILITY PANELS USING NEXT GENERATION SEQUENCING The purpose of this document is to assist providers enrolled in the Connecticut Medical Assistance Program
More informationCalendar Year (CY) 2017 Clinical Laboratory Fee Schedule (CLFS) Final Determinations
Calendar Year (CY) 2017 Clinical Laboratory Fee Schedule (CLFS) Final Determinations A. Reconsidered Tests For 2016, CMS implemented four new HCPCS G codes for definitive drug testing: G0480 (Drug test(s),
More informationGYNplus: A Genetic Test for Hereditary Ovarian and/or Uterine Cancer
GYNplus: A Genetic Test for Hereditary Ovarian and/or Uterine Cancer Causes of Hereditary Ovarian and Uterine Cancer uterine cancer ovarian cancer Sporadic 75-90% Sporadic 70-80% Hereditary, 5% Lynch syndrome
More informationpatient guide RenalNext genetic testing for hereditary kidney cancer Because knowing your risk can mean early detection and prevention
patient guide RenalNext genetic testing for hereditary kidney cancer Because knowing your risk can mean early detection and prevention Know the Basics Risk factors for developing kidney cancer include
More informationMEDICAL GENOMICS LABORATORY. Peripheral Nerve Sheath Tumor Panel by Next-Gen Sequencing (PNT-NG)
Peripheral Nerve Sheath Tumor Panel by Next-Gen Sequencing (PNT-NG) Ordering Information Acceptable specimen types: Blood (3-6ml EDTA; no time limitations associated with receipt) Saliva (OGR-575 DNA Genotek;
More informationGenetic testing in Cardiomyopathies
Genetic testing in Cardiomyopathies Silvia Giuliana Priori Cardiovascular Genetics, Langone Medical Center, New York University School of Medicine, New York, USA and Molecular Cardiology, IRCCS Fondazione
More informationNGS in Diagnostics: a practical example in hereditary cardiomyopathies
NGS in Diagnostics: a practical example in hereditary cardiomyopathies Patricia Norambuena University Hospital Motol, Prague. 2 nd Faculty of Medicine, Charles University VEP Course - November 6 th - 8th,
More informationPersonalis ACE Clinical Exome The First Test to Combine an Enhanced Clinical Exome with Genome- Scale Structural Variant Detection
Personalis ACE Clinical Exome The First Test to Combine an Enhanced Clinical Exome with Genome- Scale Structural Variant Detection Personalis, Inc. 1350 Willow Road, Suite 202, Menlo Park, California 94025
More informationHereditary Aspects of Pancreatic Cancer
Pancreatic Cancer Seminar San Francisco, CA Hereditary Aspects of Pancreatic Cancer Genetic Risk Assessment and Counseling for Familial Pancreatic Cancer February 3, 2016 Amie Blanco, MS, CGC Gordon and
More informationGenomics and Genetics in Healthcare. By Mary Knutson, RN, MSN
Genomics and Genetics in Healthcare By Mary Knutson, RN, MSN Clinical Objectives Understand the importance of genomics to provide effective nursing care Integrate genetic knowledge and skills into nursing
More informationMEDICAL GENOMICS LABORATORY. Non-NF1 RASopathy panel by Next-Gen Sequencing and Deletion/Duplication Analysis of SPRED1 (NNP-NG)
Non-NF1 RASopathy panel by Next-Gen Sequencing and Deletion/Duplication Analysis of SPRED1 (NNP-NG) Ordering Information Acceptable specimen types: Blood (3-6ml EDTA; no time limitations associated with
More informationGENETIC TESTING FOR MARFAN SYNDROME, THORACIC AORTIC ANEURYSMS AND DISSECTIONS AND RELATED DISORDERS
AND DISSECTIONS AND RELATED DISORDERS Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical
More informationWhole Exome Sequencing (WES) Whole Exome Sequencing. What Is Whole Exome Sequencing?
Whole Exome Sequencing (WES) Procedure(s) addressed by this policy: Exome (e.g., unexplained constitutional or heritable disorder or syndrome); sequence analysis Sequence analysis, each comparator exome
More informationGenetic Testing for Inherited Conditions
Genetic Testing for Inherited Conditions Policy Number: 2018-101 Effective Date: January 26, 2018 Review Date: January 26, 2018 Next Review Date: January 26, 2019 Important Information - Please Read Before
More informationAre you at risk of Hereditary Cancer? Your Guide to the Answers
Are you at risk of Hereditary Cancer? Your Guide to the Answers What is Hereditary Cancer? The genes we are born with may contribute to our risk of developing certain types of cancer, including breast,
More informationBenefits and pitfalls of new genetic tests
Benefits and pitfalls of new genetic tests Amanda Krause Division of Human Genetics, NHLS and University of the Witwatersrand Definition of Genetic Testing the analysis of human DNA, RNA, chromosomes,
More informationGenetic testing for hereditary cancer
Genetic testing for hereditary cancer THE GENETICS OF HEREDITARY CANCER About half of all men and one-third of all women in the US will develop cancer during their lifetimes. Approximately 5% to 10% of
More informationB Base excision repair, in MUTYH-associated polyposis and colorectal cancer, BRAF testing, for hereditary colorectal cancer, 696
Index Note: Page numbers of article titles are in boldface type. A Adenomatous polyposis, familial. See Familial adenomatous polyposis. Anal anastomosis, ileal-pouch, proctocolectomy with, in FAP, 591
More informationHereditary Cancer Update: What do GPOs need to know?
Hereditary Cancer Update: What do GPOs need to know? Mary McCullum, RN, MSN, CON(C) Nurse Educator, Hereditary Cancer Program BC Cancer Agency October 1, 2016 Conflict of Interest Disclosure Nothing to
More informationMSI positive MSI negative
Pritchard et al. 2014 Supplementary Figure 1 MSI positive MSI negative Hypermutated Median: 673 Average: 659.2 Non-Hypermutated Median: 37.5 Average: 43.6 Supplementary Figure 1: Somatic Mutation Burden
More informationpanel tests assessing multiple genes at the same time for the diagnosis of one or more related disorders
NGS tests panel tests assessing multiple genes at the same time for the diagnosis of one or more related disorders UKGTN website lists 13 laboratories offering a total of 56 panel test UKGTN listed panel
More informationGenetic Cancer Susceptibility Panels Using Next Generation Sequencing
Genetic Cancer Susceptibility Panels Using Next Generation Sequencing Policy Number: 2.04.93 Last Review: 7/2017 Origination: 7/2013 Next Review: 7/2018 Policy Blue Cross and Blue Shield of Kansas City
More informationConcurrent Practical Session ACMG Classification
Variant Effect Prediction Training Course 6-8 November 2017 Prague, Czech Republic Concurrent Practical Session ACMG Classification Andreas Laner / Anna Benet-Pagès 1 Content 1. Background... 3 2. Aim
More informationCancer Survivorship Symposium Cancer and Heredity January 16, Jeanne P. Homer, MS Licensed Certified Genetic Counselor
Cancer Survivorship Symposium Cancer and Heredity January 16, 2017 Jeanne P. Homer, MS Licensed Certified Genetic Counselor Outline Cancer and Heredity Hereditary Cancer Risk Assessment & Genetic testing
More informationMolecular Diagnosis of Genetic Diseases: From 1 Gene to 1000s
ROMA, 23 GIUGNO 2011 Molecular Diagnosis of Genetic Diseases: From 1 Gene to 1000s USSD Lab Genetica Medica Ospedali Riuniti Bergamo The problem What does the clinician/patient want to know?? Diagnosis,
More information10/21/ New Release, Quest Diagnostics Nichols Institute, Valencia
NEW TESTS Please Note: Not all test codes assigned to each assay are listed in the table of contents. Please refer to the complete listing on the page numbers indicated. Test Code Test Name Effective Date
More informationBUY ONE GENE, GET ONE 30 FREE! G E N E P A N E L T E S T I N G F O R H E R E D I T A R Y C A N C E R : G E T T I N G I T R I G H T THIS COULD BE YOU ONE DAY SOON: Starting out in your new OB/Gyn practice
More informationProposal form for the evaluation of a genetic test for NHS Service Gene Dossier
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name Loeys-Dietz Syndrome OMIM number for disease 609192; 608967; 610380; 610168 Disease
More informationBreast and ovarian cancer in Serbia: the importance of mutation detection in hereditary predisposition genes using NGS
Breast and ovarian cancer in Serbia: the importance of mutation detection in hereditary predisposition genes using NGS dr sc. Ana Krivokuća Laboratory for molecular genetics Institute for Oncology and
More informationHereditary Gastric Cancer
Hereditary Gastric Cancer Dr Bastiaan de Boer Consultant Pathologist Department of Anatomical Pathology PathWest Laboratory Medicine, QE II Medical Centre Clinical Associate Professor School of Pathology
More informationDNA Genetic Cancer Risk Test. Test Report
Test Report CONTENTS SECTION 1 1-1. Customer Information 1-2. Test Report Summary 1-3. Test Report Details 1-4. List of Cancers / Tumors Tested SECTION 2 2-1. About the Test 2-2. References 1 CL0040-1_B
More informationAugust 7, Dear Ms. Verma: RE: 2018 Preliminary Gapfill Payment Determinations for CY2019. Dear Ms. Verma:
ASSOCIATION FOR MOLECULAR PATHOLOGY Education. Innovation & Improved Patient Care. Advocacy. 9650 Rockville Pike. Bethesda, Maryland 20814 Tel: 301-634-7939 Fax: 301-634-7995 amp@amp.org www.amp.org August
More informationMNGenome Sequencing Test Request Form
MNGenome Sequencing Test Request Form Whole Whole Genome Exome Sequencing Note: Clinical Information and Consent Form are required for MNGenome Orders. *Please note if samples are shipping separately as
More informationWhy Test for Hereditary Cancer in Preventive Care?
Why Test for Hereditary Cancer in Preventive Care? Millions of people are sidelined by cancer. Wouldn't it be worth it for your patients to know their risk? background HEREDITARY (5-10%) More than 1 in
More informationHow many disease-causing variants in a normal person? Matthew Hurles
How many disease-causing variants in a normal person? Matthew Hurles Summary What is in a genome? What is normal? Depends on age What is a disease-causing variant? Different classes of variation Final
More informationTumorNext-HRD with OvaNext: Paired Germline and Tumor Analyses of Genes Involved in
SAMPLE REPORT Ordered By Contact ID:1251298 Example, Doctor, MD MOCKORG44 (10829) 123 Somewhere LaneSuite 4 Heaven NV 78872 US Ph:123-123-1234 Fx:123-123-1223 Org ID:8141 Normal Specimen Accession #: 00-086947
More informationBowelGene. How do I know if I am at risk? Families with hereditary bowel cancer generally show one or more of the following clues:
BowelGene BowelGene What is hereditary bowel cancer? Bowel cancer (also known as colorectal cancer) is the fourth most common cancer in the UK. Unfortunately 1 in 19 women and 1 in 14 men will develop
More informationCorporate Medical Policy
Corporate Medical Policy Genetic Testing for Marfan Syndrome, Thoracic Aortic Aneurysms and File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_testing_for_marfan_syndrome_thoracic_aortic_aneurysms_and_dissections_and_relat
More informationCHROMOSOMAL MICROARRAY (CGH+SNP)
Chromosome imbalances are a significant cause of developmental delay, mental retardation, autism spectrum disorders, dysmorphic features and/or birth defects. The imbalance of genetic material may be due
More informationLearning Objectives. Genomic Medicine and Primary Care. Clinical Applications of Genome-Level DNA Sequencing. Molecular Medicine.
Presenter Disclosure Information 9:45 10:25am Genomic Medicine and Primary Care SPEAKER Wayne W. Grody, MD, PhD, FACMG, FCAP The following relationships exist related to this presentation: Wayne W. Grody,
More informationCURRENT GENETIC TESTING TOOLS IN NEONATAL MEDICINE. Dr. Bahar Naghavi
2 CURRENT GENETIC TESTING TOOLS IN NEONATAL MEDICINE Dr. Bahar Naghavi Assistant professor of Basic Science Department, Shahid Beheshti University of Medical Sciences, Tehran,Iran 3 Introduction Over 4000
More informationThe Genetics and Genomics of Familial Heart Disease. The Genetics and Genomics of Familial Heart Disease
The Genetics and Genomics of Familial Heart Disease Bringing Precision Medicine to Life! Ray Hershberger, MD Professor Department of Internal Medicine Director, Division of Human Genetics Joint Appointment,
More informationRandom Pearls in Dysmorphology and Genetics
Random Pearls in Dysmorphology and Genetics Marilyn C. Jones Professor of Clinical Pediatrics, UCSD Wellesley College, BA Columbia University P&S, MD Pediatric Residency and Fellowship in Dysmorphology,
More informationA guide to understanding variant classification
White paper A guide to understanding variant classification In a diagnostic setting, variant classification forms the basis for clinical judgment, making proper classification of variants critical to your
More informationOriginal Policy Date
MP 2.04.76 Genetic Counseling Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Created Local Policy/ 12:2013 Return to Medical Policy Index Disclaimer
More informationComprehensive Testing for Constitutional/Mosaic Mutations with Deep Coverage via NGS
Comprehensive Testing for Constitutional/Mosaic Mutations with Deep Coverage via NGS NF1/SPRED1 and Other RASopathy Related Conditions NF1 only NGS testing and copy number analysis for the NF1 gene (NF1
More informationCPT Codes for Pharmacogenomic Tests
CPT s for Pharmacogenomic Tests The table below lists CPT codes and lab fee information for pharmacogenomic tests as established by the Centers for Medicare and Medicaid Services. It was compiled by the
More informationTest Information Sheet
OncoGeneDx: Pediatric Tumor Panel Test Information Sheet Panel Gene List: ALK, APC, CDC73, DICER1, EPCAM*, MEN1, MLH1, MSH2, MSH6, NF1, NF2, PHOX2B*, PMS2, PRK1A, PTCH1, PTEN, RB1, RET*, SMCA4, SMCB1,
More informationUsing the Bravo Liquid-Handling System for Next Generation Sequencing Sample Prep
Using the Bravo Liquid-Handling System for Next Generation Sequencing Sample Prep Tom Walsh, PhD Division of Medical Genetics University of Washington Next generation sequencing Sanger sequencing gold
More informationGenetic Cancer Susceptibility Panels Using Next Generation Sequencing
Genetic Cancer Susceptibility Panels Using Next Generation Sequencing Policy Number: 2.04.93 Last Review: 7/2018 Origination: 7/2013 Next Review: 7/2019 Policy Blue Cross and Blue Shield of Kansas City
More informationGYNplus. genetic testing for hereditary ovarian and/or uterine cancer
GYNplus genetic testing for hereditary ovarian and/or uterine cancer What Are the Causes of Hereditary Ovarian and Uterine Cancer? uterine cancer ovarian cancer sporadic 70-80% hereditary 5% Lynch syndrome
More informationGENETIC TESTING AND COUNSELING FOR HERITABLE DISORDERS
Status Active Medical and Behavioral Health Policy Section: Laboratory Policy Number: VI-09 Effective Date: 03/17/2014 Blue Cross and Blue Shield of Minnesota medical policies do not imply that members
More informationMultistep nature of cancer development. Cancer genes
Multistep nature of cancer development Phenotypic progression loss of control over cell growth/death (neoplasm) invasiveness (carcinoma) distal spread (metastatic tumor) Genetic progression multiple genetic
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Genetic Cancer Susceptibility Panels Using Next Generation Sequencing Page 1 of 35 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Genetic Cancer Susceptibility
More informationpatient guide BrainTumorNext genetic testing for hereditary brain tumors Because knowing your risk can mean early detection and prevention
patient guide BrainTumorNext genetic testing for hereditary brain tumors Because knowing your risk can mean early detection and prevention Know the Basics Brain tumors are the most common tumor/cancer
More informationCancer genetics
Cancer genetics General information about tumorogenesis. Cancer induced by viruses. The role of somatic mutations in cancer production. Oncogenes and Tumor Suppressor Genes (TSG). Hereditary cancer. 1
More information